Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2015 May;37(5):722-6.
doi: 10.1002/hed.23664. Epub 2014 Jun 18.

Efficacy of nelfinavir as monotherapy in refractory adenoid cystic carcinoma: Results of a phase II clinical trial

Andrew C Hoover  1 , Mohammed M Milhem, Carryn M Anderson, Wenqing Sun, Brian J Smith, Henry T Hoffman, John M Buatti
Affiliations
Clinical Trial

Efficacy of nelfinavir as monotherapy in refractory adenoid cystic carcinoma: Results of a phase II clinical trial

Andrew C Hoover et al. Head Neck. 2015 May.

Abstract

Background: Adenoid cystic carcinomas (ACCs) are malignant salivary gland tumors noteworthy for high rates of late failure with limited salvage therapy options. We have previously shown increased Akt signaling is common in ACC and the human immunodeficiency virus (HIV) protease inhibitor nelfinavir (NFV) inhibits in vitro tumor growth by suppressing Akt signaling. This phase II trial was conducted to determine progression-free survival in response to NFV in patients with recurrent/endstage ACC who have failed standard therapies.

Methods: Eligible patients had recurrent or end-stage ACC and measureable disease per Response Evaluation Criteria in Solid Tumors (RECIST) criteria. NFV was provided at 1250 mg twice daily.

Results: Among 15 trial participants, median progression-free survival was 5.5 months (lower 95% bound 4.4 months). No patient achieved a RECIST partial or complete response to therapy.

Conclusion: NFV monotherapy does not result in a meaningful improvement in clinical outcomes among patients with recurrent ACC.

Keywords: Akt; adenoid cystic carcinoma; head and neck cancer; nelfinavir; salivary gland cancer.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Figure 2
Figure 2
See this image and copyright information in PMC

References

    1. Chummun S, et al. Adenoid cystic carcinoma of the head and neck. Br J Plast Surg. 2001;54(6):476–80. - PubMed
    1. Ries LAG YJ, Keel GE, Eisner MP, Lin YD, Horner M-J, editors. SEER Survival Monograph: Cancer Survival Among Adults: U.S. SEER Program, 1988-2001, Patient and Tumor Characteristics. National Cancer Institute; Bethesda, MD: 2007. SEER Program, NIH Pub. No. 07-6215. 2007.
    1. Khan AJ, et al. Adenoid cystic carcinoma: a retrospective clinical review. Int J Cancer. 2001;96(3):149–58. - PubMed
    1. Dodd RL, Slevin NJ. Salivary gland adenoid cystic carcinoma: a review of chemotherapy and molecular therapies. Oral Oncol. 2006;42(8):759–69. - PubMed
    1. Gupta AK, et al. Signaling pathways in adenoid cystic cancers: implications for treatment. Cancer Biol Ther. 2009;8(20):1947–51. - PMC - PubMed

Publication types

MeSH terms